SAB Biotherapeutics (NASDAQ:SABS) Price Target Cut to $7.00 by Analysts at HC Wainwright

Key Points

• HC Wainwright cut its price target to $7.00 (from $9.00) while maintaining a "buy" rating, which the brokerage says implies about an 82.29% upside from the stock's previous close.
• Analyst views are mixed but overall favorable: MarketBeat data shows a consensus rating of "Moderate Buy" with an average target of $9.60 and individual targets ranging from $7 to $15 across recent reports.
• SAB Biotherapeutics is a clinical‑stage biotech trading around $3.84 with a market cap near $183 million, negative earnings (loss per share of $0.46 last quarter), and very high liquidity ratios.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) had its target price reduced by stock analysts at HC Wainwright from $9.00 to $7.00 in a report released on Tuesday,Benzinga reports. The brokerage currently has a "buy" rating on the stock. HC Wainwright's target price would suggest a potential upside of 82.29% from the stock's previous close.

A number of other research analysts have also recently commented on SABS. Weiss Ratings reaffirmed a "sell (d)" rating on shares of SAB Biotherapeutics in a research note on Monday, December 29th. UBS Group assumed coverage on shares of SAB Biotherapeutics in a research report on Wednesday, January 7th. They set a "buy" rating and a $7.00 target price on the stock. Wall Street Zen raised SAB Biotherapeutics from a "sell" rating to a "hold" rating in a research note on Saturday, November 22nd. Chardan Capital reiterated a "buy" rating and issued a $12.00 target price on shares of SAB Biotherapeutics in a report on Thursday, December 18th. Finally, Guggenheim started coverage on shares of SAB Biotherapeutics in a report on Friday, December 19th. They set a "buy" rating and a $15.00 target price on the stock. One analyst has rated the stock with a Strong Buy rating, four have assigned a Buy rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, SAB Biotherapeutics presently has an average rating of "Moderate Buy" and a consensus target price of $9.60.

SAB Biotherapeutics Stock Performance

SAB Biotherapeutics stock opened at $3.84 on Tuesday. The company has a market cap of $182.82 million, a PE ratio of -1.24 and a beta of 0.59. SAB Biotherapeutics has a twelve month low of $1.00 and a twelve month high of $6.60. The company has a quick ratio of 10.50, a current ratio of 10.49 and a debt-to-equity ratio of 0.02. The company's 50-day moving average price is $3.97 and its 200-day moving average price is $3.32.

SAB Biotherapeutics (NASDAQ:SABS - Get Free Report) last posted its quarterly earnings data on Monday, March 9th. The company reported ($0.46) earnings per share (EPS) for the quarter. On average, equities research analysts forecast that SAB Biotherapeutics will post -3.69 EPS for the current fiscal year.

Institutional Trading of SAB Biotherapeutics

Institutional investors have recently bought and sold shares of the stock. HB Wealth Management LLC purchased a new position in shares of SAB Biotherapeutics in the third quarter worth $618,000. Goldman Sachs Group Inc. grew its stake in SAB Biotherapeutics by 357.6% during the 4th quarter. Goldman Sachs Group Inc. now owns 51,348 shares of the company's stock valued at $192,000 after purchasing an additional 40,127 shares during the last quarter. Perceptive Advisors LLC purchased a new stake in SAB Biotherapeutics during the 4th quarter valued at about $3,004,000. Geode Capital Management LLC lifted its holdings in shares of SAB Biotherapeutics by 39.4% during the fourth quarter. Geode Capital Management LLC now owns 119,517 shares of the company's stock worth $447,000 after purchasing an additional 33,799 shares during the period. Finally, Verition Fund Management LLC purchased a new stake in shares of SAB Biotherapeutics in the 4th quarter valued at $100,000. 7.82% of the stock is currently owned by institutional investors and hedge funds.

About SAB Biotherapeutics

SAB Biotherapeutics, Inc is a clinical-stage biotechnology company headquartered in Sioux Falls, South Dakota, that focuses on developing fully human polyclonal antibody therapeutics. The company's proprietary platform, known as Tc Bovine®, uses genetically engineered cattle to generate large quantities of human antibodies tailored to target specific infectious agents or disease-related antigens. This approach is designed to combine the broad-spectrum coverage of polyclonal antibody therapies with the scalability and consistency required for clinical development and commercial use.

The company's lead programs are directed primarily at infectious diseases.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.